ASND Ascendis Pharma A/S
$263.52▲ +0.87%
Healthcare
Other
After hours
$263.52▲ +0.00%
Sep 11, 7:52 PM ET
Volume 443.6K
Avg Volume (10D) 595.7K
Key Metrics & Fundamentals
Market Cap
$17.33B
P/E Ratio
20.3
Div Yield
–%
52W Range
186.05 - 282.15
% vs 50 MA
2.33%
% vs 200 MA
12.85%
RSI-14
55.8
MACD Histogram
+0.6100
Beta (1Y vs SPY)
0.30
Free Cash Flow
$270.73M
Gross Rev
$339.29M
Gross Profit
$311.63M
EBITDA
$242.01M
COGS
$27.66M
Operating Exp
$91.16M
Operating Income
$220.47M
EBIT
$220.47M
Pretax Income
$230.09M
Net Income
$206.97M
EPS (Diluted)
2.83
Price & Volume History
Loading chart…
Recent News
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Benzinga · Sep 10, 2026 1:52 PM
Ascendis Pharma Insider Sold Shares Worth $810,570, According to a Recent SEC Filing
MT Newswires · Sep 9, 2026 9:06 PM
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
GlobeNewswire · Sep 9, 2026 8:01 PM
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
GlobeNewswire · Sep 9, 2026 8:23 AM
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 8, 2026 8:01 PM
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
GlobeNewswire · Sep 7, 2026 11:00 AM
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
Insider Monkey · Sep 4, 2026 4:26 PM
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus
Simply Wall St. · Sep 4, 2026 8:18 AM
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing
Simply Wall St. · Sep 4, 2026 7:08 AM
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Zacks · Sep 3, 2026 4:28 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See ASND's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.